APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

HIV Prevention Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HIV Prevention Drug Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchHIV Prevention Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Prevention Drug Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal HIV Prevention Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Prevention Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Prevention Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global HIV Prevention Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HIV Prevention Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HIV Prevention Drug market include Gilead Sciences and ViiV Healthcare among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HIV Prevention Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV Prevention Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV Prevention Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HIV Prevention Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

HIV Prevention Drug Segment by Company

Gilead Sciences

ViiV Healthcare

HIV Prevention Drug Segment by Type

Lenacapavir

Cabotegravir

HIV Prevention Drug Segment by Application

Hospital

Clinic

Others

HIV Prevention Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global HIV Prevention Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions HIV Prevention Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HIV Prevention Drug significant trends, drivers, influence factors in global and regions.

6. To analyze HIV Prevention Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Prevention Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Prevention Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Prevention Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HIV Prevention Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HIV Prevention Drug industry.

Chapter 3: Detailed analysis of HIV Prevention Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of HIV Prevention Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of HIV Prevention Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HIV Prevention Drug Industry Trends Table 2. HIV Prevention Drug Industry Drivers Table 3. HIV Prevention Drug Industry Opportunities and Challenges Table 4. HIV Prevention Drug Industry Restraints Table 5. Global HIV Prevention Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HIV Prevention Drug Revenue Share by Company (2021-2026) Table 7. Global HIV Prevention Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global HIV Prevention Drug Sales Volume Share by Company (2021-2026) Table 9. Global HIV Prevention Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global HIV Prevention Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global HIV Prevention Drug Key Company Manufacturing Base & Headquarters Table 12. Global HIV Prevention Drug Company, Product Type & Application Table 13. Global HIV Prevention Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global HIV Prevention Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lenacapavir Table 18. Significant Companies of Cabotegravir Table 19. Global HIV Prevention Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global HIV Prevention Drug Sales Volume by Type (2021-2026) & (K Units) Table 21. Global HIV Prevention Drug Sales Volume by Type (2027-2032) & (K Units) Table 22. Global HIV Prevention Drug Sales Volume Share by Type (2021-2026) Table 23. Global HIV Prevention Drug Sales Volume Share by Type (2027-2032) Table 24. Global HIV Prevention Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global HIV Prevention Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global HIV Prevention Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global HIV Prevention Drug Sales Value Share by Type (2021-2026) Table 28. Global HIV Prevention Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global HIV Prevention Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global HIV Prevention Drug Sales Volume by Application (2021-2026) & (K Units) Table 34. Global HIV Prevention Drug Sales Volume by Application (2027-2032) & (K Units) Table 35. Global HIV Prevention Drug Sales Volume Share by Application (2021-2026) Table 36. Global HIV Prevention Drug Sales Volume Share by Application (2027-2032) Table 37. Global HIV Prevention Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global HIV Prevention Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global HIV Prevention Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global HIV Prevention Drug Sales Value Share by Application (2021-2026) Table 41. Global HIV Prevention Drug Sales Value Share by Application (2027-2032) Table 42. Global HIV Prevention Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global HIV Prevention Drug Sales by Region (2021-2026) & (K Units) Table 44. Global HIV Prevention Drug Sales Market Share by Region (2021-2026) Table 45. Global HIV Prevention Drug Sales by Region (2027-2032) & (K Units) Table 46. Global HIV Prevention Drug Sales Market Share by Region (2027-2032) Table 47. Global HIV Prevention Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global HIV Prevention Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global HIV Prevention Drug Sales Value Share by Region (2021-2026) Table 50. Global HIV Prevention Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global HIV Prevention Drug Sales Value Share by Region (2027-2032) Table 52. Global HIV Prevention Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global HIV Prevention Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global HIV Prevention Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global HIV Prevention Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 57. Global HIV Prevention Drug Sales Market Share by Country (2021-2026) Table 58. Global HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 59. Global HIV Prevention Drug Sales Market Share by Country (2027-2032) Table 60. Global HIV Prevention Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global HIV Prevention Drug Sales Value Market Share by Country (2021-2026) Table 62. Global HIV Prevention Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global HIV Prevention Drug Sales Value Market Share by Country (2027-2032) Table 64. Gilead Sciences Company Information Table 65. Gilead Sciences Business Overview Table 66. Gilead Sciences HIV Prevention Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Gilead Sciences HIV Prevention Drug Product Portfolio Table 68. Gilead Sciences Recent Development Table 69. ViiV Healthcare Company Information Table 70. ViiV Healthcare Business Overview Table 71. ViiV Healthcare HIV Prevention Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. ViiV Healthcare HIV Prevention Drug Product Portfolio Table 73. ViiV Healthcare Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. HIV Prevention Drug Distributors List Table 77. HIV Prevention Drug Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. HIV Prevention Drug Product Image Figure 2. Global HIV Prevention Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Prevention Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global HIV Prevention Drug Sales (2021-2032) & (K Units) Figure 5. Global HIV Prevention Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global HIV Prevention Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lenacapavir Image Figure 10. Cabotegravir Image Figure 11. Global HIV Prevention Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global HIV Prevention Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global HIV Prevention Drug Sales Volume Share by Type (2021-2032) Figure 14. Global HIV Prevention Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global HIV Prevention Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global HIV Prevention Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global HIV Prevention Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global HIV Prevention Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global HIV Prevention Drug Sales Volume Share by Application (2021-2032) Figure 23. Global HIV Prevention Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global HIV Prevention Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global HIV Prevention Drug Sales Value Share by Application (2021-2032) Figure 26. Global HIV Prevention Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global HIV Prevention Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global HIV Prevention Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global HIV Prevention Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America HIV Prevention Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America HIV Prevention Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe HIV Prevention Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe HIV Prevention Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific HIV Prevention Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific HIV Prevention Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America HIV Prevention Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America HIV Prevention Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa HIV Prevention Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa HIV Prevention Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt HIV Prevention Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. HIV Prevention Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. HIV Prevention Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Lenacapavir
  • Cabotegravir
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Gilead Sciences
  • ViiV Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global HIV Prevention Drug Sales Value (2021-2032)
  4. 1.2.2 Global HIV Prevention Drug Sales Volume (2021-2032)
  5. 1.2.3 Global HIV Prevention Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 HIV Prevention Drug Market Dynamics
  1. 2.1 HIV Prevention Drug Industry Trends
  2. 2.2 HIV Prevention Drug Industry Drivers
  3. 2.3 HIV Prevention Drug Industry Opportunities and Challenges
  4. 2.4 HIV Prevention Drug Industry Restraints
3 HIV Prevention Drug Market by Company
  1. 3.1 Global HIV Prevention Drug Company Revenue Ranking in 2025
  2. 3.2 Global HIV Prevention Drug Revenue by Company (2021-2026)
  3. 3.3 Global HIV Prevention Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global HIV Prevention Drug Average Price by Company (2021-2026)
  5. 3.5 Global HIV Prevention Drug Company Ranking (2024-2026)
  6. 3.6 Global HIV Prevention Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global HIV Prevention Drug Company Product Type and Application
  8. 3.8 Global HIV Prevention Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global HIV Prevention Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 HIV Prevention Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 HIV Prevention Drug Market by Type
  1. 4.1 HIV Prevention Drug Type Introduction
  2. 4.1.1 Lenacapavir
  3. 4.1.2 Cabotegravir
  4. 4.2 Global HIV Prevention Drug Sales Volume by Type
  5. 4.2.1 Global HIV Prevention Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global HIV Prevention Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global HIV Prevention Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global HIV Prevention Drug Sales Value by Type
  9. 4.3.1 Global HIV Prevention Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global HIV Prevention Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global HIV Prevention Drug Sales Value Share by Type (2021-2032)
5 HIV Prevention Drug Market by Application
  1. 5.1 HIV Prevention Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global HIV Prevention Drug Sales Volume by Application
  6. 5.2.1 Global HIV Prevention Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HIV Prevention Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global HIV Prevention Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global HIV Prevention Drug Sales Value by Application
  10. 5.3.1 Global HIV Prevention Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global HIV Prevention Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global HIV Prevention Drug Sales Value Share by Application (2021-2032)
6 HIV Prevention Drug Regional Sales and Value Analysis
  1. 6.1 Global HIV Prevention Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV Prevention Drug Sales by Region (2021-2032)
  3. 6.2.1 Global HIV Prevention Drug Sales by Region: 2021-2026
  4. 6.2.2 Global HIV Prevention Drug Sales by Region (2027-2032)
  5. 6.3 Global HIV Prevention Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global HIV Prevention Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global HIV Prevention Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global HIV Prevention Drug Sales Value by Region (2027-2032)
  9. 6.5 Global HIV Prevention Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America HIV Prevention Drug Sales Value (2021-2032)
  12. 6.6.2 North America HIV Prevention Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe HIV Prevention Drug Sales Value (2021-2032)
  15. 6.7.2 Europe HIV Prevention Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific HIV Prevention Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific HIV Prevention Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America HIV Prevention Drug Sales Value (2021-2032)
  21. 6.9.2 South America HIV Prevention Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa HIV Prevention Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa HIV Prevention Drug Sales Value Share by Country, 2025 VS 2032
7 HIV Prevention Drug Country-level Sales and Value Analysis
  1. 7.1 Global HIV Prevention Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HIV Prevention Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global HIV Prevention Drug Sales by Country (2021-2032)
  4. 7.3.1 Global HIV Prevention Drug Sales by Country (2021-2026)
  5. 7.3.2 Global HIV Prevention Drug Sales by Country (2027-2032)
  6. 7.4 Global HIV Prevention Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global HIV Prevention Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global HIV Prevention Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt HIV Prevention Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt HIV Prevention Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt HIV Prevention Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences
  2. 8.1.1 Gilead Sciences Company Information
  3. 8.1.2 Gilead Sciences Business Overview
  4. 8.1.3 Gilead Sciences HIV Prevention Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences HIV Prevention Drug Product Portfolio
  6. 8.1.5 Gilead Sciences Recent Developments
  7. 8.2 ViiV Healthcare
  8. 8.2.1 ViiV Healthcare Company Information
  9. 8.2.2 ViiV Healthcare Business Overview
  10. 8.2.3 ViiV Healthcare HIV Prevention Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 ViiV Healthcare HIV Prevention Drug Product Portfolio
  12. 8.2.5 ViiV Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HIV Prevention Drug Value Chain Analysis
  2. 9.1.1 HIV Prevention Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HIV Prevention Drug Sales Mode & Process
  6. 9.2 HIV Prevention Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HIV Prevention Drug Distributors
  9. 9.2.3 HIV Prevention Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst